Articles related to MYELOMA

In an editorial accompanying the final results of the TOURMALINE-MM1 study, Drs. D’Souza and Lonial question whether overall survival (OS) is “still the gold standard for demonstrating the value of a novel agent in phase III trials early in the disease course given the current treatment landscape.”

According to the results of a study published in Annals of Hematology, two novel analytical approaches for detecting malignant plasma cell clones appear to accurately indicate the course of multiple myeloma (MM) and may be valuable for monitoring patients with serologically nontrackable disease.

Jacob Laubach, MD, at the Dana-Farber Cancer Institute provides a summary of the most recent update from the GRIFFIN trial, assessing daratumumab plus lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients. After 24 months of maintenance therapy or treatment discontinuation (median follow-up of 38.6 months), the rate of stringent complete response (sCR) was 66% in the D-RVd treatment arm versus 47.4% in the RVd treatment arm. At the time of data collection, median PFS had not been reached in either arm but is trending towards favoring D-RVd versus RVd. The estimated 36-month PFS rate was 88.9% for D-RVd and 81.2% for RVd.

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates of complete response and cytokine release syndrome severity in the younger than 60 population. However, there was no difference in progression-free or overall survival, regardless of age. Design: Cohort review of 154 patients with NHL or MM receiving CAR T-cells

“It’s inconceivable!” This famous line and exchange from the 1987 classic film The Princess Bride, along with the fates of the characters Vizzini and Inigo Montoya, provide the fulcrum for this Journal of Clinical Oncology (JCO) editorial, which highlights the phase III TOURMALINE-MM1 trial and its seemingly “negative” findings in multiple myeloma (MM). Are we considering the inconceivable? Do we know what the word even means?

From the pages of Oncology Times comes the latest approvals, designations, and new indications from the U.S. Food and Drug Administration (FDA) for oncology drugs. Stories include new approvals in multiple myeloma, esophageal or gastroesophageal junction (GEJ) carcinoma, non-small cell lung cancer (NSCLC), anaplastic lymphoma, and more.